23
Mar

Austin, Texas, biotech Aeglea Biotherapeutics raised $44 million in Series B cash to bankroll its enzyme-replacement therapy for a rare metabolic disorder, with Eli Lilly and Novartis leading the round.

…read more

Source: Novartis, Lilly lead a $44M round for rare disease biotech Aeglea

    

0 No comments